Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention F.M. Leweke, J.K. Mueller, B.Lange, S. Fritze, C.E. Topor, D. Koethe, C. Rohleder CNS Drugs, 2018 Jul;32(7):605-619. doi: 10.1007/s40263-018-0539-z. Abstract The term schizophrenia describes a group of multifaceted psychiatric conditions causing significant impairment of the quality of life of affected patients. Although multiple pharmacological treatment options exist, e.g. first- or second-generation antipsychotics, these therapeutics often cause disturbing side effects, such as extrapyramidal symptoms, prolactin increase, sexual dysfunction and/or metabolic syndrome. Furthermore, cognitive impairments and negative symptoms, two factors significantly influencing the course and outcome, are not sufficiently addressed by the available [...]
Lire la suiteChildhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids E. Appiah-Kusi, R. Wilson, M.Colizzi, E. Foglia, Sagnik Bhattacharyya, et al. Psychological Medicine, 2019. DOI: https://doi.org/10.1017/S0033291719001946 Published online by Cambridge University Press: 19 August 2019 Abstract BackgroundEvidence has been accumulating regarding alterations in components of the endocannabinoid system in patients with psychosis. Of all the putative risk factors associated with psychosis, being at clinical high-risk for psychosis (CHR) has the strongest association with the onset of psychosis, and exposure to childhood trauma has been linked to an increased risk of development of psychotic disorder. We aimed to investigate whether being at-risk for [...]
Lire la suite